VIR Vir Biotechnology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VIR

Price (delayed)

$11.09

Market cap

$1.88B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.84

Enterprise value

$1.68B

?
Relative Growth: Rel. Growth: 75
Relative Strength: Rel. Strength: 91
Relative Valuation: Rel. Valuation: 11
Relative Profitability: Rel. Profitability: 43

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage ...

Highlights
The net income has surged by 54% year-on-year and by 43% since the previous quarter
The EPS has surged by 54% year-on-year and by 41% since the previous quarter
VIR's quick ratio is down by 15% year-on-year and by 13% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.vir.bio
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of VIR

VIR stock price

How has the Vir Biotechnology stock price performed over time
Intraday
-3.57%
1 week
5.42%
1 month
13.39%
1 year
114.51%
YTD
83.91%
QTD
8.83%

Financial performance

How have Vir Biotechnology's revenue and profit performed over time
Revenue
$303.23M
Gross profit
$303.21M
Operating income
-$280.19M
Net income
-$251.68M
Gross margin
100%
Net margin
-83%
The company's operating margin has surged by 97% YoY and by 87% QoQ
The net margin has soared by 97% YoY and by 88% from the previous quarter
The company's operating income has surged by 54% YoY and by 41% QoQ
The net income has surged by 54% year-on-year and by 43% since the previous quarter

Price vs fundamentals

How does VIR's price correlate with its fundamentals

Growth

What is Vir Biotechnology's growth rate over time

Valuation

What is Vir Biotechnology stock price valuation
VIR P/E details
P/E
N/A
P/B
1.9
P/S
6.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.54
The EPS has surged by 54% year-on-year and by 41% since the previous quarter
VIR's price to book (P/B) is 52% higher than its last 4 quarters average of 1.3 and 23% higher than its 5-year quarterly average of 1.6
Vir Biotechnology's equity has increased by 21% from the previous quarter and by 3.7% YoY
The price to sales (P/S) is 70% lower than the last 4 quarters average of 21.3 and 57% lower than the 5-year quarterly average of 14.7

Efficiency

How efficient is Vir Biotechnology business performance
The return on sales has surged by 97% year-on-year and by 88% since the previous quarter
Vir Biotechnology's return on assets has increased by 44% QoQ and by 42% YoY
Vir Biotechnology's return on equity has increased by 44% QoQ and by 40% YoY
The return on invested capital rose by 44% since the previous quarter and by 44% year-on-year

Dividends

What is VIR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VIR.

Financial health

How did Vir Biotechnology financials performed over time
Vir Biotechnology's total assets has increased by 18% QoQ
VIR's quick ratio is down by 15% year-on-year and by 13% since the previous quarter
The debt is 91% less than the equity
Vir Biotechnology's equity has increased by 21% from the previous quarter and by 3.7% YoY
The debt to equity fell by 18% QoQ and by 10% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.